Stewart-Jones Guillaume, Wadle Andreas, Hombach Anja, Shenderov Eugene, Held Gerhard, Fischer Eliane, Kleber Sascha, Nuber Natko, Stenner-Liewen Frank, Bauer Stefan, McMichael Andrew, Knuth Alexander, Abken Hinrich, Hombach Andreas A, Cerundolo Vincenzo, Jones E Yvonne, Renner Christoph
Division of Structural Biology, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, United Kingdom.
Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5784-8. doi: 10.1073/pnas.0901425106. Epub 2009 Mar 23.
T-cell interaction with a target cell is a key event in the adaptive immune response and primarily driven by T-cell receptor (TCR) recognition of peptide-MHC (pMHC) complexes. TCR avidity for a given pMHC is determined by number of MHC molecules, availability of coreceptors, and TCR affinity for MHC or peptide, respectively, with peptide recognition being the most important factor to confer target specificity. Here we present high-resolution crystal structures of 2 Fab antibodies in complex with the immunodominant NY-ESO-1(157-165) peptide analogue (SLLMWITQV) presented by HLA-A0201 and compare them with a TCR recognizing the same pMHC. Binding to the central methionine-tryptophan peptide motif and orientation of binding were almost identical for Fabs and TCR. As the MW "peg" dominates the contacts between Fab and peptide, we estimated the contributions of individual amino acids between the Fab and peptide to provide the rational basis for a peptide-focused second-generation, high-affinity antibody library. The final Fab candidate achieved better peptide binding by 2 light-chain mutations, giving a 20-fold affinity improvement to 2-4 nM, exceeding the affinity of the TCR by 1,000-fold. The high-affinity Fab when grafted as recombinant TCR on T cells conferred specific killing of HLA-A0201/NY-ESO-1(157-165) target cells. In summary, we prove that affinity maturation of antibodies mimicking a TCR is possible and provide a strategy for engineering high-affinity antibodies that can be used in targeting specific pMHC complexes for diagnostic and therapeutic purposes.
T细胞与靶细胞的相互作用是适应性免疫反应中的关键事件,主要由T细胞受体(TCR)对肽 - 主要组织相容性复合体(pMHC)复合物的识别所驱动。TCR对给定pMHC的亲和力分别由MHC分子数量、共受体可用性以及TCR对MHC或肽的亲和力决定,其中肽识别是赋予靶标特异性的最重要因素。在此,我们展示了与由HLA - A0201呈递的免疫显性NY - ESO - 1(157 - 165)肽类似物(SLLMWITQV)形成复合物的2种Fab抗体的高分辨率晶体结构,并将它们与识别相同pMHC的TCR进行比较。Fab和TCR与中央甲硫氨酸 - 色氨酸肽基序的结合以及结合方向几乎相同。由于MW“挂钩”主导了Fab与肽之间的接触,我们估计了Fab与肽之间各个氨基酸的贡献,为以肽为重点的第二代高亲和力抗体文库提供了合理依据。最终的Fab候选物通过2个轻链突变实现了更好的肽结合,亲和力提高了20倍,达到2 - 4 nM,比TCR的亲和力高出1000倍。当作为重组TCR移植到T细胞上时,高亲和力Fab赋予了对HLA - A0201/NY - ESO - 1(157 - 165)靶细胞的特异性杀伤作用。总之,我们证明了模拟TCR的抗体亲和力成熟是可能的,并提供了一种工程化高亲和力抗体的策略,可用于靶向特定pMHC复合物以用于诊断和治疗目的。
Proc Natl Acad Sci U S A. 2009-4-7
bioRxiv. 2024-12-20
Nat Biotechnol. 2024-12-13
Acta Pharm Sin B. 2024-9
Immunol Rev. 2023-11
Eur J Immunol. 2007-11
Proc Natl Acad Sci U S A. 2005-12-27